US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Evommune

6.96

-0.2500-3.47%

Volume:420.06K

Turnover:2.97M

Market Cap:252.59M

PE:-2.67

High:7.28

Open:7.18

Low:6.91

Close:7.21

52wk High:33.20

52wk Low:6.91

Shares:36.29M

Float Shares:19.98M

Volume Ratio:1.58

T/O Rate:2.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.6090

EPS(LYR):-11.2228

ROE:-52.11%

ROA:-31.99%

PB:0.91

PE(LYR):-0.62

Loading ...

Overview Company News Filings

Analysts Conflicted on These NA Names: Fiserv (FISV), Evommune, Inc. (EVMN) and Waystar Holding Corp. (WAY)

Evommune Posts Corporate Presentation Outlining Phase 2 Inflammation-Drug Pipeline Focusing on Evo756, Evo301

Evommune Q2 FY26 Net Loss Widens to $32.25 Million

Evommune Starts Phase 2b Trial of Evo756 for Migraine Prevention

Evommune - Top-Line Data from Phase 2B Trial Expected in 2027

THOMSON REUTERS

Evommune Initiates Phase 2B Clinical Trial of Mrgprx2 Inhibitor Evo756 in Migraine Prophylaxis

THOMSON REUTERS

Evommune CFO Kyle Carver Acquires 1,000 Common Shares for $13,260

Independent Director of Evommune Arthur Kirsch Buys More Stock

Simply Wall St.

Evommune Director Arthur S. Kirsch Reports Purchase of $133,000 in Common Shares

Evommune Publishes Corporate Deck Outlining Chronic Inflammation Drug Pipeline, Led by Evo756 and Evo301 Programs

Stifel Nicolaus Sticks to Their Buy Rating for Evommune, Inc. (EVMN)

Evommune’s EVO756 Migraine Trial: What Investors Should Know About This New Phase 2 Study

Evommune’s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market

Evommune is Maintained at Overweight by Morgan Stanley

HC Wainwright Downgrades Evommune to Neutral From Buy

MT Newswires Live

U.S. Research Roundup- Comcast, Honeywell Aerospace, Qualys

Evommune price target lowered to $28 from $53 at Clear Street

Evommune Halts Urticaria Drug Development After Phase 2b Trial Fails Primary Goal, Shifts Focus to Dermatitis and Migraine

Top Midday Decliners

MT Newswires Live

Evommune Cut to Market Perform from Outperform by William Blair

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/EVMN/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EVMN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","market":"US","secType":"STK","nameCN":"Evommune","latestPrice":6.96,"timestamp":1790955068695,"preClose":7.21,"halted":0,"volume":420060,"delay":0,"changeRate":-0.03467406380027739,"floatShares":19982000,"shares":36292113,"eps":-2.609,"marketStatus":"Trading","change":-0.25,"latestTime":"10-02 11:31:08 EDT","open":7.18,"high":7.28,"low":6.91,"amount":2974967.41464,"amplitude":0.051318,"askPrice":6.96,"askSize":254,"bidPrice":6.95,"bidSize":1,"shortable":0,"etf":0,"ttmEps":-2.609,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1790971200000},"marketStatusCode":2,"adr":0,"listingDate":1762405200000,"exchange":"NYSE","adjPreClose":7.21,"preHourTrading":{"tag":"盘前","latestPrice":7.02,"preClose":7.21,"latestTime":"09:15 EDT","volume":942,"amount":6587.562372,"timestamp":1790946940212,"change":-0.19,"changeRate":-0.026352,"amplitude":0.009709},"postHourTrading":{"tag":"盘后","latestPrice":7.2,"preClose":7.21,"latestTime":"19:40 EDT","volume":29965,"amount":215232.8508,"timestamp":1790898004365,"change":-0.01,"changeRate":-0.001387,"amplitude":0.059639},"volumeRatio":1.576145,"impliedVol":1.6189,"impliedVolPercentile":0.7522},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","floatShares":19982000,"roa":"-31.99%","roe":"-52.11%","lyrEps":-11.222761,"volumeRatio":1.576145,"shares":36292113,"dividePrice":0,"high":7.28,"amplitude":0.051318,"preClose":7.21,"low":6.91,"week52Low":6.91,"pbRate":"0.91","psRate":"25.26","week52High":33.2,"institutionHeld":0,"latestPrice":6.96,"committee":-0.992157,"eps":-2.609,"divideRate":0,"volume":420060,"delay":0,"ttmEps":-2.609,"open":7.18,"prevYearClose":17.12,"prevWeekClose":8.49,"prevMonthClose":8.26,"prevQuarterClose":8.26,"fiveDayClose":8.49,"twentyDayClose":12,"sixtyDayClose":13.51},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EVMN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"EVMN","fiscalQuarterEnding":"2026/06","expectedEps":-0.68,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-0.89},{"market":"US","date":"2026-05-07","symbol":"EVMN","fiscalQuarterEnding":"2026/03","expectedEps":-0.83,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-0.64},{"market":"US","date":"2026-03-05","symbol":"EVMN","fiscalQuarterEnding":"2025/12","expectedEps":-0.82,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-1.43}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EVMN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EVMN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5833,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5833,"analysts":12,"updateTime":1787803200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EVMN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EVMN","date":"2026-10-01","current":-2.667689,"percent":1,"low":-16.229076,"twenty":-12.303359,"median":-9.479385,"eighty":-5.516493,"high":-3.16657,"avg":-9.281325,"sd":3.229597,"marketCap":299772853},"quantilePoints":[{"date":"2025-11-07","current":-9.395174,"twenty":-7.823584,"median":-7.430686,"eighty":-7.430686,"marketCap":608469038},{"date":"2025-11-14","current":-8.461694,"twenty":-9.04686,"median":-8.505813,"eighty":-7.430686,"marketCap":548013143},{"date":"2025-11-21","current":-8.689259,"twenty":-9.04686,"median":-8.689259,"eighty":-7.430686,"marketCap":562751147},{"date":"2025-11-28","current":-9.618094,"twenty":-9.051504,"median":-8.707835,"eighty":-8.049291,"marketCap":622906267},{"date":"2025-12-05","current":-10.184684,"twenty":-9.618094,"median":-8.986487,"eighty":-8.483986,"marketCap":659600890},{"date":"2025-12-12","current":-9.657505,"twenty":-9.633858,"median":-9.000419,"eighty":-8.483986,"marketCap":592227156},{"date":"2025-12-19","current":-7.716136,"twenty":-9.618094,"median":-8.986487,"eighty":-8.244704,"marketCap":473176635},{"date":"2025-12-26","current":-9.042428,"twenty":-9.528926,"median":-9.016673,"eighty":-8.355807,"marketCap":554508795},{"date":"2026-01-02","current":-8.800817,"twenty":-9.392482,"median":-9.003431,"eighty":-8.469125,"marketCap":539692472},{"date":"2026-01-09","current":-9.37143,"twenty":-9.380689,"median":-8.972554,"eighty":-8.293747,"marketCap":574684215},{"date":"2026-01-16","current":-10.075701,"twenty":-9.649623,"median":-9.019686,"eighty":-8.354639,"marketCap":617872222},{"date":"2026-01-23","current":-9.710714,"twenty":-9.690151,"median":-9.037572,"eighty":-8.461694,"marketCap":595490116},{"date":"2026-01-30","current":-11.129537,"twenty":-9.775997,"median":-9.042428,"eighty":-8.498847,"marketCap":682496613},{"date":"2026-02-06","current":-8.564346,"twenty":-9.775997,"median":-9.064213,"eighty":-8.549933,"marketCap":525191389},{"date":"2026-02-13","current":-14.332171,"twenty":-9.885497,"median":-9.065437,"eighty":-8.563866,"marketCap":878891712},{"date":"2026-02-20","current":-14.769127,"twenty":-10.094711,"median":-9.253195,"eighty":-8.56425,"marketCap":905687191},{"date":"2026-02-27","current":-13.689588,"twenty":-10.579486,"median":-9.338016,"eighty":-8.621921,"marketCap":839486596},{"date":"2026-03-06","current":-11.484529,"twenty":-11.200535,"median":-9.381712,"eighty":-8.67867,"marketCap":790939493},{"date":"2026-03-13","current":-12.018327,"twenty":-12.245567,"median":-9.479385,"eighty":-8.689259,"marketCap":827702188},{"date":"2026-03-20","current":-12.321662,"twenty":-12.396972,"median":-9.618094,"eighty":-8.70412,"marketCap":848592844},{"date":"2026-03-27","current":-12.379191,"twenty":-12.362455,"median":-9.695292,"eighty":-8.728757,"marketCap":852554865},{"date":"2026-04-02","current":-11.725452,"twenty":-12.336306,"median":-9.710846,"eighty":-8.771001,"marketCap":807531900},{"date":"2026-04-10","current":-14.983685,"twenty":-12.570606,"median":-9.775997,"eighty":-8.798761,"marketCap":1031926357},{"date":"2026-04-17","current":-14.000462,"twenty":-13.015147,"median":-9.975459,"eighty":-8.828576,"marketCap":964211818},{"date":"2026-04-24","current":-13.514081,"twenty":-13.425068,"median":-10.075701,"eighty":-8.877926,"marketCap":930714732},{"date":"2026-05-01","current":-12.44718,"twenty":-13.370677,"median":-10.26642,"eighty":-8.898489,"marketCap":857237253},{"date":"2026-05-08","current":-11.767292,"twenty":-13.351187,"median":-10.76455,"eighty":-8.934568,"marketCap":810413370},{"date":"2026-05-15","current":-10.76944,"twenty":-13.300701,"median":-10.81684,"eighty":-8.966981,"marketCap":818337411},{"date":"2026-05-22","current":-11.162865,"twenty":-13.208546,"median":-10.76944,"eighty":-8.989273,"marketCap":848232660},{"date":"2026-05-29","current":-11.058584,"twenty":-13.135327,"median":-10.864241,"eighty":-9.002829,"marketCap":840308618},{"date":"2026-06-05","current":-9.807205,"twenty":-13.084182,"median":-10.80499,"eighty":-9.017037,"marketCap":745220116},{"date":"2026-06-12","current":-9.807205,"twenty":-13.030837,"median":-10.755219,"eighty":-9.036643,"marketCap":745220116},{"date":"2026-06-18","current":-9.788245,"twenty":-12.946112,"median":-10.53322,"eighty":-9.042258,"marketCap":743779381},{"date":"2026-06-26","current":-11.43779,"twenty":-12.867664,"median":-10.624868,"eighty":-9.042428,"marketCap":869123316},{"date":"2026-07-02","current":-6.07677,"twenty":-12.855112,"median":-10.547048,"eighty":-9.032928,"marketCap":461755529},{"date":"2026-07-10","current":-6.403835,"twenty":-12.813273,"median":-10.376014,"eighty":-8.958621,"marketCap":486608205},{"date":"2026-07-17","current":-5.550622,"twenty":-12.635456,"median":-10.177718,"eighty":-8.800817,"marketCap":421775136},{"date":"2026-07-24","current":-5.36576,"twenty":-12.598847,"median":-10.075701,"eighty":-8.689259,"marketCap":407727971},{"date":"2026-07-31","current":-5.37998,"twenty":-12.561192,"median":-10.06542,"eighty":-8.56425,"marketCap":408808522},{"date":"2026-08-07","current":-5.090694,"twenty":-12.489019,"median":-9.881902,"eighty":-8.43493,"marketCap":481925817},{"date":"2026-08-14","current":-5.393903,"twenty":-12.464961,"median":-9.807205,"eighty":-8.177768,"marketCap":510630029},{"date":"2026-08-21","current":-5.202222,"twenty":-12.450318,"median":-9.782121,"eighty":-7.430686,"marketCap":492483973},{"date":"2026-08-28","current":-5.16772,"twenty":-12.413708,"median":-9.712404,"eighty":-6.987812,"marketCap":489217683},{"date":"2026-09-04","current":-4.600344,"twenty":-12.384421,"median":-9.710846,"eighty":-6.276801,"marketCap":435505356},{"date":"2026-09-11","current":-4.048303,"twenty":-12.366639,"median":-9.695292,"eighty":-6.160195,"marketCap":383244713},{"date":"2026-09-18","current":-3.592102,"twenty":-12.358271,"median":-9.618094,"eighty":-5.832183,"marketCap":340057098},{"date":"2026-09-25","current":-3.373586,"twenty":-12.336306,"median":-9.537021,"eighty":-5.714629,"marketCap":319370594},{"date":"2026-10-01","current":-3.16657,"twenty":-12.303359,"median":-9.479385,"eighty":-5.516493,"marketCap":299772853}],"updateTime":1790955068981},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EVMN\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657066615","title":"Analysts Conflicted on These NA Names: Fiserv (FISV), Evommune, Inc. (EVMN) and Waystar Holding Corp. (WAY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657066615","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657066615?lang=en_us&edition=fundamental","pubTime":"2026-08-07 16:40","pubTimestamp":1786092008,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the NA sector with new ratings on Fiserv (FISV), Evommune, Inc. (EVMN) and Waystar Holding Corp. (WAY). Fis...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-na-names-fiserv-fisv-evommune-inc-evmn-and-waystar-holding-corp-way-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-na-names-fiserv-fisv-evommune-inc-evmn-and-waystar-holding-corp-way-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0980610538.SGD","LU1169589451.USD","BK4141","LU1169590202.USD","BK4585","LU1861220207.SGD","LU1046421795.USD","LU0354030511.USD","EVMN","FINX","LU1823568750.SGD","BK4139","LU0648001328.SGD","LU0757428866.USD","LU1815336091.USD","NA","BK4588","LU0070302665.USD","LU1201861249.SGD","LU0130103400.USD","LU2125909916.SGD","LU0320765489.SGD","LU1201861165.SGD","LU0648000940.SGD","BK4167","WAY","FISV","LU0354030438.USD","BK4106","BK4227","LU1861217088.USD","LU0130102774.USD","LU1923622291.USD","LU0208291251.USD","LU2125909759.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657669650","title":"Evommune Posts Corporate Presentation Outlining Phase 2 Inflammation-Drug Pipeline Focusing on Evo756, Evo301","url":"https://stock-news.laohu8.com/highlight/detail?id=2657669650","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657669650?lang=en_us&edition=fundamental","pubTime":"2026-08-07 06:11","pubTimestamp":1786054289,"startTime":"0","endTime":"0","summary":"Evommune posts corporate presentation outlining Phase 2 inflammation-drug pipeline focusing on EVO756, EVO301Evommune outlined two Phase 2 programs in chronic inflammatory diseases, led by EVO756 in a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLcdShYX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650670","title":"Evommune Q2 FY26 Net Loss Widens to $32.25 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650670","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650670?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:17","pubTimestamp":1786047455,"startTime":"0","endTime":"0","summary":"Evommune Q2 FY26 net loss widens to $32.25 millionEvommune posted a Q2 net loss of USD 32.25 million, widening from USD 13.57 million a year earlier.R&D expense rose 34.49% to USD 26.41 million, while","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL1n2hZk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655872837","title":"Evommune Starts Phase 2b Trial of Evo756 for Migraine Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2655872837","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655872837?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:01","pubTimestamp":1785412874,"startTime":"0","endTime":"0","summary":"Evommune starts Phase 2b trial of EVO756 for migraine preventionEvommune launched a Phase 2b trial of oral MRGPRX2 inhibitor EVO756 for migraine prevention, dosing the first patient.Top-line results h","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDLrzbqn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655874090","title":"Evommune - Top-Line Data from Phase 2B Trial Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2655874090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655874090?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nTUA8LHQNZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655387476","title":"Evommune Initiates Phase 2B Clinical Trial of Mrgprx2 Inhibitor Evo756 in Migraine Prophylaxis","url":"https://stock-news.laohu8.com/highlight/detail?id=2655387476","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655387476?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nTUA8LHQNZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650158610","title":"Evommune CFO Kyle Carver Acquires 1,000 Common Shares for $13,260","url":"https://stock-news.laohu8.com/highlight/detail?id=2650158610","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650158610?lang=en_us&edition=fundamental","pubTime":"2026-07-11 08:00","pubTimestamp":1783728046,"startTime":"0","endTime":"0","summary":"Evommune CFO Kyle Carver acquires 1,000 common shares for $13,260Evommune CFO Kyle Carver bought 1,000 common shares at USD 13.26.Direct holdings rose to 60,335 shares.Disclaimer:This news brief was c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260711:nNDL4JpcFl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Evommune CFO Kyle Carver Acquires 1,000 Common Shares for $13,260","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650110138","title":"Independent Director of Evommune Arthur Kirsch Buys More Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2650110138","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650110138?lang=en_us&edition=fundamental","pubTime":"2026-07-10 19:35","pubTimestamp":1783683354,"startTime":"0","endTime":"0","summary":"Investors who take an interest in Evommune, Inc. ( NYSE:EVMN ) should definitely note that the Independent Director...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-evmn/evommune/news/independent-director-of-evommune-arthur-kirsch-buys-more-sto","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-evmn/evommune/news/independent-director-of-evommune-arthur-kirsch-buys-more-sto","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650691432","title":"Evommune Director Arthur S. Kirsch Reports Purchase of $133,000 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2650691432","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650691432?lang=en_us&edition=fundamental","pubTime":"2026-07-09 08:00","pubTimestamp":1783555257,"startTime":"0","endTime":"0","summary":"Evommune director Arthur S. Kirsch reports purchase of $133,000 in common sharesEvommune director Arthur S. Kirsch bought 10,000 common shares at USD 13.3, raising beneficial ownership to 10,000 share","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nNDL4D2tWD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Evommune Director Arthur S. Kirsch Reports Purchase of $133,000 in Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649675371","title":"Evommune Publishes Corporate Deck Outlining Chronic Inflammation Drug Pipeline, Led by Evo756 and Evo301 Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2649675371","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649675371?lang=en_us&edition=fundamental","pubTime":"2026-07-07 01:32","pubTimestamp":1783359122,"startTime":"0","endTime":"0","summary":"Evommune publishes corporate deck outlining chronic inflammation drug pipeline, led by EVO756 and EVO301 programsEvommune highlighted two Phase 2 inflammation assets, led by oral MRGPRX2 antagonist EV","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDL9Rh4JP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649645924","title":"Stifel Nicolaus Sticks to Their Buy Rating for Evommune, Inc. (EVMN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2649645924","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649645924?lang=en_us&edition=fundamental","pubTime":"2026-07-06 13:55","pubTimestamp":1783317335,"startTime":"0","endTime":"0","summary":"In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Evommune, Inc., with a price target of $54.00. Thomps...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-their-buy-rating-for-evommune-inc-evmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-their-buy-rating-for-evommune-inc-evmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648654790","title":"Evommune’s EVO756 Migraine Trial: What Investors Should Know About This New Phase 2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2648654790","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648654790?lang=en_us&edition=fundamental","pubTime":"2026-07-02 00:31","pubTimestamp":1782923460,"startTime":"0","endTime":"0","summary":"Evommune, Inc. ($EVMN) announced an update on their ongoing clinical study. The Phase 2 study “A Randomized, Double-Blind, Placebo Controlled Study...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/evommunes-evo756-migraine-trial-what-investors-should-know-about-this-new-phase-2-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/evommunes-evo756-migraine-trial-what-investors-should-know-about-this-new-phase-2-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN","BK4139","BK4211","ISBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648547135","title":"Evommune’s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2648547135","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648547135?lang=en_us&edition=fundamental","pubTime":"2026-07-02 00:30","pubTimestamp":1782923439,"startTime":"0","endTime":"0","summary":"Evommune, Inc. ($EVMN) announced an update on their ongoing clinical study. Evommune, Inc. has completed a Phase 2b trial of EVO756 in adults with ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/evommunes-evo756-trial-completion-signals-key-milestone-in-chronic-urticaria-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/evommunes-evo756-trial-completion-signals-key-milestone-in-chronic-urticaria-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647591635","title":"Evommune is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2647591635","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647591635?lang=en_us&edition=fundamental","pubTime":"2026-06-30 21:06","pubTimestamp":1782824760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EVMN/analyst-ratings(END) Dow Jones NewswiresJune 30, 2026 09:06 ET","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647300545","title":"HC Wainwright Downgrades Evommune to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2647300545","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647300545?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:14","pubTimestamp":1782818047,"startTime":"0","endTime":"0","summary":"HC Wainwright Downgrades Evommune to Neutral From Buy","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647533196","title":"U.S. Research Roundup- Comcast, Honeywell Aerospace, Qualys","url":"https://stock-news.laohu8.com/highlight/detail?id=2647533196","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647533196?lang=en_us&edition=fundamental","pubTime":"2026-06-30 15:51","pubTimestamp":1782805890,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Comcast, Honeywell Aerospace, QualysJune 30 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Comcast","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nL8N4320EF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNR","EOG","HWKN","EVRG","CE","CMCSA","DIS","HONA","AMYY","GOOX","GOOW","EXPE","CHTR","AMDS","AADX","DAL","AMDG","GNRC","BROS","AMDY","GOOP","GOOY","ABVX","BKNG","CNXC","FBIN","FCBC","FOXF","AAL","EVMN","AMD","AMDL","HRMY","ASTH","GOU","BKU","AMDD","FUL","TECH","BAC","EVH","DOW","AMDU","GSX","CELH","AA","AVAV","HON","GOOGL","AIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647302943","title":"Evommune price target lowered to $28 from $53 at Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2647302943","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647302943?lang=en_us&edition=fundamental","pubTime":"2026-06-30 04:20","pubTimestamp":1782764455,"startTime":"0","endTime":"0","summary":"Clear Street lowered the firm’s price target on Evommune (EVMN) to $28 from $53 and keeps a Buy rating on the shares after the company announced th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-price-target-lowered-to-28-from-53-at-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-price-target-lowered-to-28-from-53-at-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151653547","title":"Evommune Halts Urticaria Drug Development After Phase 2b Trial Fails Primary Goal, Shifts Focus to Dermatitis and Migraine","url":"https://stock-news.laohu8.com/highlight/detail?id=1151653547","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151653547?lang=en_us&edition=fundamental","pubTime":"2026-06-30 03:50","pubTimestamp":1782762639,"startTime":"0","endTime":"0","summary":"The biotechnology firm Evommune announced top-line results from a Phase 2b clinical trial of EVO756 for moderate-to-severe chronic spontaneous urticaria on Monday, revealing the study did not meet...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647309875","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2647309875","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647309875?lang=en_us&edition=fundamental","pubTime":"2026-06-30 01:49","pubTimestamp":1782755397,"startTime":"0","endTime":"0","summary":"Evommune's  top-line results from a phase 2b trial of EVO756 to treat adults with moderate-to-severe chronic spontaneous urticaria failed to meet the primary endpoint at any dosage, according to a statement released Monday.Shares sank 39% as intraday trading volume surged to over 5.9 million from a daily average of about 415,000.Solidion Technology  said Monday it plans to opportunistically acquire shares of SpaceX  as a long-term strategic treasury asset, using a modest portion of its cash reserves.Shares of Solidion slumped 20%, with intraday trading volume climbing to about 2.4 million from a daily average of roughly 2.8 million.Martin Marietta Materials  agreed to combine with limestone supplier Lhoist North America in a $13.5 billion deal.Shares dropped 6.6% as intraday trading volume rose to more than 759,300 from a daily average of about 509,000.Price: 15.35, Change: -9.83, Percent Change: -39.04","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","SPCG","SPCM","LU0300736492.USD","G3B.SI","SPAL","SSPC","SG9999001077.SGD","GAB.SI","MLM.AU","BK4096","BK4588","BK4548","SPCX","STI.SI","BK4089","SPCH","BK4585","EVMN","ES3.SI","BK4011","BK4139","SPCF","LU0300736062.USD","SPCQ","LU2237438978.USD","STI","SNK","MLM","LOFF","SPAX","SPCU","LU0053666078.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647306334","title":"Evommune Cut to Market Perform from Outperform by William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2647306334","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647306334?lang=en_us&edition=fundamental","pubTime":"2026-06-30 01:01","pubTimestamp":1782752460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EVMN/analyst-ratings(END) Dow Jones NewswiresJune 29, 2026 13:01 ET","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":106,"code":"91000000","status":"200"}]}}